EUCTR2005-005519-12-IT进行中（未招募）不适用
A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Tdap Vaccine GSK Boostrix and Chiron Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Boostrix, Or One Dose of Chiron Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years - ND
CHIRO0 个研究点目标入组 1,000 人开始时间: 2006年6月23日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 11-17 years of age inclusive who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment; OR 18-25 years of age, mentally competent, and able to give the written informed consent prior to study entry 2. available for all visits and telephone calls scheduled for the study 3. in good health as determined by o medical history o physical assessment o clinical judgment of the investigator 4. who have received the primary immunization with a vaccine containing DT or DTaP antigens and a T, Td or Tdap booster dose at least 5 years prior to study entry.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. who are unwilling to give their written assent subjects aged 11-17 years , when applicable 2. who subjects aged 18-25 years or whose parents or legal guardians for subjects aged 11-17 years are unwilling or unable to give written informed consent to participate in the study; 3. who and/or whose parents or legal guardians are perceived to be unreliable or unavailable for the duration of the study period; 4. who had a previous ascertained or suspected disease caused by N. meningitidis; 5. who had household contact with and/or intimate exposure to an individual with culture-proven N meningitidis infection within 60 days prior to enrollment; 6. who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen s licensed or investigational Exception Receipt of OMP-containing Hib vaccines is permitted ; 7. who have received any investigational agents or vaccines within 90 days prior to enrollment or who expect to receive an investigational agent or vaccine prior to the completion of the study; 8. who have received any licensed vaccines within one month prior to enrollment or for whom receipt of a licensed vaccine is anticipated within study period Exception Influenza vaccine may be administered up to 15 days prior to study vaccination and no less than 15 days after study vaccination ; 9. who have received a live viral vaccine within 60 days prior to enrollment; 10. who have experienced within the 7 days prior to enrollment significant acute or chronic infection for example requiring systemic antibiotic treatment or antiviral therapy or have experienced fever e.g., axillary temperature 38 C within 3 days prior to enrollment; 11. who have any serious acute, chronic or progressive disease e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition . Exception Subjects with mild asthma are eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids are not eligible for enrollment ; 12. who have epilepsy or any progressive neurological disease; 13. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component; 14. who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from for example o receipt of immunosuppressive therapy within 30 days prior to enrollment any systemic corticosteroid administered for more than 5 days, or in a daily dose 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy o receipt of immunostimulants o receipt of parenteral immunoglobulin preparation, blood products, and /or plasma derivatives within 90 days prior to enrollment and for the full length of the study 15. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time; 16. who have Down s syndrome or other known cytogenic disorders; 17. who are pregnant or unwilling to do a pregnancy test or attest to not being pregnant; 18. who are not taking or unwilling to take sufficient measures to avoid pregnancy occurring for the duration of the study period. If sexually active, the subject must have been using one of the accepted birth control methods at least two months prior
研究者
相似试验
进行中（未招募）
不适用
Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Together and/or Separately According to Different Schedules to Healthy SubjectsSafety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to healthy adult subjectsMedDRA version: 14.1Level: PTClassification code 10037742Term: RabiesSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10023123Term: Japanese encephalitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: HLTClassification code 10037743Term: Rabies viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-005173-23-DEovartis Vaccines and Diagnostics GmbH660
进行中（未招募）
不适用
Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Together and/or Separately According to Different Schedules to Healthy SubjectsEUCTR2011-005173-23-ATovartis Vaccines and Diagnostics GmbH660
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineEUCTR2015-000728-27-EESeqirus UK Limited6,790
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineProfylaxis for Influenza virusMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-000728-27-PLSeqirus UK Limited10,692
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineProfylaxis for Influenza virusMedDRA version: 19.1 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000728-27-BGSeqirus UK Limited6,790